Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

Journal of Infectious Diseases

Volumn 175, Issue 4, 1997, Pages 781-789

  Davey Jr , Richard T ^a   Chaitt, Doreen G ^b   Piscitelli, Stephen C ^b   Wells, Mary ^b   Kovacs, Joseph A ^b   Walker, Robert E ^b   Falloon, Judith ^b   Polis, Michael A ^b   Metcalf, Julia A ^b   Masur, Henry ^b   Fyfe, Gwendolyn ^b   Lane, H Clifford ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ADULT; ARTHRALGIA; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; LYMPHOCYTE COUNT; MALE; MAXIMUM PERMISSIBLE DOSE; MYALGIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 16944364282     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513971     Document Type: Article

References (16)

1. Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983;72:398-403.
2. Hefeneider SH, Conlon PJ, Henney CS, Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol 1983;130:220-7.
3. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995; 332:567-75.
4. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
5. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndrome 1991;4: 11-23.
6. Dewar R, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type I burden in human plasma. J Infect Dis 1994;170:1172-9.
7. Piscitelli SC, Wells M, Metcalf JA, et al. Pharmacokinetics and pharmaco-dynamics of subcutaneously administered interleukin-2 in HIV-infected patients. Pharmacotherapy 1996;16:754-9.
8. Volberding P, Moody DJ, Beardslee D, Bradley EC, Wofsy CB. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. AIDS Res Hum Retroviruses 1987;3:115-24.
9. Ernst M, Kern P, Flad HD, Ulmer AJ. Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC). J Clin Immunol 1986;6:170-81.
10. Klimas N, Patarca R, Walling J, et al. Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion. AIDS 1994;8:1073-81.
11. 3: results of a randomized, controlled trial. N Engl J Med 1996;335:1350-6.
12. Teppler H, Kaplan G, Smith K, et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993;167:291-8.
13. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993;167:519-25.
14. McMahon DK, Armstrong JA, Huang XL, et al. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine. AIDS 1994;8:59-66.
15. Davey RT, Chaitt D, Kovacs J, Walker R, et al. Subcutaneous interleukin-2 therapy is capable of inducing marked sustained increases in CD4 counts in early HIV-infected patients [abstract We.b.290]. In: XIth International Conference on AIDS (Vancouver, Canada). Vancouver: Transcontinental Printing, 1996.
16. Falloon J, Owen C, Kovacs J, et al. MK-639 (Merck HIV Protease Inhibitor) with interleukin-2 (IL2) in HIV [abstract I176]. In: Program and abstracts of the 35th International Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:236.